C.H. Robinson Second Quarter 2025 Earnings Release and Conference Call Scheduled for Wednesday, July 30, 2025
Presentation slides and a simultaneous audio webcast of the conference call may be accessed at http://investor.chrobinson.com. To participate in the conference call by telephone, please call ten minutes early by dialing 877-269-7756.
An audio replay will be available at http://investor.chrobinson.com.
About C.H. Robinson
C.H. Robinson delivers logistics like no one else™. Companies around the world look to us to reimagine supply chains, advance freight technology, and solve logistics challenges—from the simple to the most complex. 83,000 customers and 450,000 contract carriers in our network trust us to manage 37 million shipments and $23 billion in freight annually. Through our unmatched expertise, unrivaled scale, and tailored solutions, we ensure the seamless delivery of goods across industries and continents via truckload, less-than-truckload, ocean, air, and beyond. As a responsible global citizen, we make supply chains more sustainable and proudly contribute millions to the causes that matter most to our employees. For more information, visit us at chrobinson.com. (Nasdaq: CHRW)
CHRW-IR
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
ExchangeRight Secures 50 Lease Renewals and Sustains 100% Rent Collection for its Essential Income REIT
PASADENA, Calif.--(BUSINESS WIRE)--ExchangeRight has announced that through Q2 2025 the company maintained 100% rent collections and executed 50 lease renewals across the company's entire net lease platform, including all properties in the Essential Income REIT. This strong asset management resulted in a net lease occupancy rate of 99.86% as of June 30, 2025, among the highest in the net lease sector. Through Q2 2025, ExchangeRight maintained 100% rent collections and executed 50 lease renewals across the company's entire net lease platform, including all properties in ExchangeRight's Essential Income REIT. Share ExchangeRight's Asset Management Update as of June 30, 2025 Leasing Performance Highlights (2023 – Q2 2025) 50 lease renewals executed with 11 national tenants operating essential businesses, including industry-leading retailers and service providers Average lease extension of 64 months, reinforcing long-term tenant commitments and supporting consistent cash flow to investors 6.15% weighted average rent increases secured on renewed leases, enhancing overall rental income and portfolio performance Net Lease Platform Occupancy 99.86% occupancy rate for ExchangeRight's net-leased assets under management as of June 30, 2025, reflecting one of the highest occupancy rates in the net lease sector 25:1 ratio of lease renewals and re-leases to vacancies, demonstrating strong tenant retention and successful re-leasing strategies Only 17 leases across the Net Lease Platform (0.60% of total platform rents) with expirations in the next 12 months, minimizing near-term rollover risk Past performance does not guarantee future results. 'Our disciplined Asset Management and Leasing teams continue to deliver strong results on behalf of investors, supporting ExchangeRight's reputation for proactive and investor-centric operational management,' said Tim Williams, director of asset management. 'These results benefit ExchangeRight's investors by supporting stable monthly distributions to empower investors to be secure, free, and generous.' 'As we execute our aggregation strategy and scale our REIT platform, each renewal strengthens long-term income potential for investors,' said Joshua Ungerecht, a managing partner at ExchangeRight. 'Our focus remains on stewarding investor capital faithfully by prioritizing operational excellence, creditworthy tenants, and recession-resilient assets throughout all market cycles.' About ExchangeRight ExchangeRight and its affiliates' vertically integrated platform features more than $6.6 billion in assets under management that are diversified across over 1,300 properties, and 26 million square feet throughout 47 states, as of July 31, 2025. ExchangeRight pursues its passion to empower people to be secure, free, and generous through its Essential Income REIT and 1031 DST portfolios that target secure capital, stable income, and strategic exits, all of which have historically met or exceeded investor projections since ExchangeRight's inception. On behalf of investors nationwide, the company structures and manages net-leased portfolios of assets backed primarily by investment-grade corporations that have successfully operated in the necessity-based retail and healthcare industries. Past performance does not guarantee future results. Please visit for more information.
Yahoo
23 minutes ago
- Yahoo
Discovering Undiscovered Gems in the US Market August 2025
As the U.S. stock market navigates through a period of mixed performance with the Dow Jones Industrial Average reaching new highs while the S&P 500 and Nasdaq face declines, investors are keenly observing potential shifts in Federal Reserve policies that could impact future market dynamics. In this environment, identifying stocks with strong fundamentals and growth potential becomes crucial, especially as major indices fluctuate and economic indicators remain uncertain. Top 10 Undiscovered Gems With Strong Fundamentals In The United States Name Debt To Equity Revenue Growth Earnings Growth Health Rating Southern Michigan Bancorp 117.38% 8.87% 4.89% ★★★★★★ Oakworth Capital 87.50% 15.82% 9.79% ★★★★★★ ASA Gold and Precious Metals NA 12.79% -0.59% ★★★★★★ Sound Financial Bancorp 34.70% 2.11% -11.08% ★★★★★★ Metalpha Technology Holding NA 75.66% 28.60% ★★★★★★ First Northern Community Bancorp NA 8.05% 12.27% ★★★★★★ Senstar Technologies NA -20.82% 14.32% ★★★★★★ Valhi 44.30% 1.10% -1.40% ★★★★★☆ Pure Cycle 5.02% 4.35% -2.25% ★★★★★☆ Rich Sparkle Holdings 26.73% -6.13% 1.75% ★★★★★☆ Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener. Let's review some notable picks from our screened stocks. Carter Bankshares Simply Wall St Value Rating: ★★★★☆☆ Overview: Carter Bankshares, Inc. is the bank holding company for Carter Bank & Trust, offering a range of retail and commercial banking products and insurance services in the United States, with a market capitalization of $414.86 million. Operations: Carter Bankshares generates revenue primarily from its banking segment, totaling $153.12 million. Carter Bankshares, with assets totaling US$4.8 billion and equity of US$405.6 million, has been making waves recently. The company reported a significant earnings growth of 152.5% over the past year, outperforming the industry average of 12.5%. Despite this impressive performance, it grapples with a high level of bad loans at 6.7%, coupled with an insufficient allowance for bad loans at 28%. Recently added to multiple Russell indexes and completing a share buyback worth US$10.41 million for 171,899 shares, CARE seems poised for continued attention in investment circles due to its strong earnings momentum and strategic moves. Delve into the full analysis health report here for a deeper understanding of Carter Bankshares. Learn about Carter Bankshares' historical performance. Northrim BanCorp Simply Wall St Value Rating: ★★★★★★ Overview: Northrim BanCorp, Inc. is the bank holding company for Northrim Bank, offering commercial banking products and services to businesses and professional individuals, with a market cap of $476.66 million. Operations: Northrim BanCorp generates revenue primarily through its Community Banking segment with $121.89 million, followed by Home Mortgage Lending at $35.57 million and Specialty Finance contributing $6.39 million. Northrim BanCorp, with assets totaling US$3.2 billion and equity of US$290.2 million, stands out for its robust financial health. The company boasts total deposits of US$2.8 billion against loans of US$2.2 billion, indicating a solid funding base primarily from customer deposits—considered low risk compared to external borrowing. Its allowance for bad loans is sufficient at 190%, covering non-performing loans which are just 0.5% of total loans, well within acceptable limits. Recent earnings growth was impressive at 39%, far surpassing the industry average of 12%. Northrim's inclusion in multiple Russell indices highlights its recognition as a promising player in the market landscape. Get an in-depth perspective on Northrim BanCorp's performance by reading our health report here. Examine Northrim BanCorp's past performance report to understand how it has performed in the past. Shore Bancshares Simply Wall St Value Rating: ★★★★★★ Overview: Shore Bancshares, Inc. functions as a bank holding company for Shore United Bank, N.A., with a market capitalization of $525.66 million. Operations: Shore Bancshares generates revenue primarily from its community banking segment, which reported $208.21 million. Shore Bancshares, with total assets of US$6.0 billion and equity of US$565.2 million, presents a robust financial profile. Its net interest margin stands at 3.1%, supported by total deposits of US$5.3 billion and loans amounting to US$4.8 billion. The bank maintains a sufficient allowance for bad loans at 344% coverage, with non-performing loans at just 0.3%. Trading at a price-to-earnings ratio of 9.9x, it offers good value compared to the broader market's 18.8x average, while its earnings growth last year outpaced the industry significantly by reaching an impressive 166%. Dive into the specifics of Shore Bancshares here with our thorough health report. Gain insights into Shore Bancshares' past trends and performance with our Past report. Key Takeaways Take a closer look at our US Undiscovered Gems With Strong Fundamentals list of 286 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CARE NRIM and SHBI. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
34 minutes ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade
